Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23590375 | 0.76 | LMNA (0.35) | SMN1; SMN2NPC1RAB9AHTTMAPT | |
| SCHEMBL803110 | 0.70 | NUDT1 (0.34) | SMN1; SMN2NPC1RAB9AHTTALDH1A1 | |
| SCHEMBL10100319 | 0.68 | NPC1 (0.38) | SMN1; SMN2NPC1RAB9AHTTALDH1A1 | |
| SCHEMBL29808161 | 0.68 | ALOX15 (0.43) | SMN1; SMN2NPC1RAB9AHTTMAPT | |
| SCHEMBL30481675 | 0.67 | — | — | |
| SCHEMBL805491 | 0.67 | — | — | |
| SCHEMBL8738333 | 0.66 | PIK3CG (0.36) | SMN1; SMN2NPC1RAB9AHTTMAPT | |
| SCHEMBL15945546 | 0.66 | NPC1 (0.45) | SMN1; SMN2NPC1RAB9AHTTPIK3CG | |
| SCHEMBL20161132 | 0.66 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTMAPT | |
| SCHEMBL506677 | 0.64 | PIK3CG (0.35) | SMN1; SMN2NPC1RAB9AHTTPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198220-A1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-07-01 | — | — | US | disclosed |
| US-11001563-B2 | SSAO inhibitor | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-05-11 | — | — | US | disclosed |
| US-20200115352-A1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001563-B2 | SSAO inhibitor | SSB, ASAH2, AOX1 | SMN1; SMN2 1539/4885NPC1 567/4885RAB9A 3567/4885 |
| US-20210198220-A1 | SSAO INHIBITOR | SSB, ASAH2, AOX1 | SMN1; SMN2 1539/4885NPC1 567/4885RAB9A 3567/4885 |
| US-20200115352-A1 | SSAO INHIBITOR | SSB, ASAH2, AOX1 | SMN1; SMN2 1539/4885NPC1 567/4885RAB9A 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.